Challenges of Assessing Community Mortality Due to Respiratory Viruses in Children Aged Less Than 5 Years.
challenges
community mortality
respiratory syncytial virus
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
02 09 2021
02 09 2021
Historique:
entrez:
2
9
2021
pubmed:
3
9
2021
medline:
8
10
2021
Statut:
ppublish
Résumé
Estimating the real impact of respiratory syncytial virus (RSV) disease is key for the development of vaccines and treatments. Ascertaining the burden of community mortality due to RSV is challenging due to the lack of primary data. Therefore, conducting observational studies to determine the factors associated with community mortality due to the virus in developing countries is important. Our aim in this study was to describe the obstacles, gaps, and challenges that investigators face in low-income, vulnerable regions in 4 developing countries on 3 continents. The main obstacles and challenges of ascertaining community mortality due to RSV were defining strategies to consent families for testing before burial, sampling individuals at the household level, supporting bereaved parents with different cultural and religious backgrounds, establishing tailored strategies for studies in challenging settings, and integrating RSV mortality data from nasopharyngeal samples. Detailed logistical planning based on population sociodemographic information, grief counseling, staff training, and a multidisciplinary approach with adequate laboratory infrastructure is critical to successful observational community-based RSV studies.
Sections du résumé
BACKGROUND
Estimating the real impact of respiratory syncytial virus (RSV) disease is key for the development of vaccines and treatments. Ascertaining the burden of community mortality due to RSV is challenging due to the lack of primary data. Therefore, conducting observational studies to determine the factors associated with community mortality due to the virus in developing countries is important.
OBJECTIVE
Our aim in this study was to describe the obstacles, gaps, and challenges that investigators face in low-income, vulnerable regions in 4 developing countries on 3 continents.
RESULTS
The main obstacles and challenges of ascertaining community mortality due to RSV were defining strategies to consent families for testing before burial, sampling individuals at the household level, supporting bereaved parents with different cultural and religious backgrounds, establishing tailored strategies for studies in challenging settings, and integrating RSV mortality data from nasopharyngeal samples.
CONCLUSION
Detailed logistical planning based on population sociodemographic information, grief counseling, staff training, and a multidisciplinary approach with adequate laboratory infrastructure is critical to successful observational community-based RSV studies.
Identifiants
pubmed: 34472573
pii: 6362479
doi: 10.1093/cid/ciab487
pmc: PMC8411250
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S248-S254Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Clin Infect Dis. 2019 Oct 9;69(Suppl 4):S262-S273
pubmed: 31598664
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
PLoS Med. 2017 Jun 20;14(6):e1002317
pubmed: 28632739
Am J Respir Crit Care Med. 2013 May 1;187(9):983-90
pubmed: 23449690
Lancet. 2013 Apr 20;381(9875):1380-1390
pubmed: 23369797
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Diagn Microbiol Infect Dis. 2016 Jan;84(1):80-86
pubmed: 26508103
Am J Respir Crit Care Med. 2017 Jan 1;195(1):96-103
pubmed: 27331632
JAMA. 2010 May 26;303(20):2051-7
pubmed: 20501927
BMC Med. 2014 Jan 09;12:5
pubmed: 24405531
Clin Infect Dis. 2019 Oct 9;69(Suppl 4):S333-S341
pubmed: 31598661
Int J Epidemiol. 2010 Aug;39(4):1103-14
pubmed: 20519334
J Infect Dis. 2019 Jan 9;219(3):358-364
pubmed: 30165655
Lancet Respir Med. 2016 May;4(5):345-7
pubmed: 27304556
Lung India. 2016 Jul-Aug;33(4):372-80
pubmed: 27578928